Ganirelix

Indications:

• Prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation in assisted reproductive technologies (ART) like in-vitro fertilization (IVF).

Mechanism of Action: Ganirelix works by competitively blocking the GnRH receptors on the pituitary gland, thus preventing the release of LH and follicle-stimulating hormone (FSH). This inhibition prevents premature ovulation, allowing for more controlled ovarian hyperstimulation.

Pharmacokinetics:

• Absorption: Rapidly and almost completely absorbed after subcutaneous administration.
• Distribution: Rapidly distributed in the body.
• Metabolism: Mainly hepatic.
• Excretion: Primarily through the kidneys.

Form: Ganirelix API is typically presented as a white to off-white lyophilized powder.